Peptide Association LLC is a for-profit company. We receive compensation from the clinical providers listed on this site. We are not an accrediting body, a licensing board, or a government-affiliated organization. See exactly how we make money.
Intranasal Insulin
Overview
Intranasal insulin involves the administration of regular human insulin via nasal spray to target central nervous system insulin receptors without causing systemic hypoglycemia. Insulin signaling in the brain is implicated in synaptic plasticity, glucose metabolism, and amyloid clearance, providing a rationale for cognitive enhancement in insulin-resistant states and Alzheimer disease.
Mechanism of Action
Intranasal delivery bypasses the blood-brain barrier via olfactory and trigeminal nerve pathways.
Research Summary & Key Findings
Multiple phase II trials have evaluated intranasal insulin in mild cognitive impairment and early Alzheimer disease, with some studies reporting modest improvements in memory and executive function. A large multicenter trial is ongoing, and prior smaller studies have been published in journals including Neurology and the Journal of Alzheimer's Disease over the past decade.
Clinical Status
Intranasal Insulin is currently undergoing clinical trials. It is not yet FDA-approved and is available only through clinical research settings or investigational protocols.
Administration Routes
References
Primary literature
- PubMed: "Intranasal Insulin"
Peer-reviewed literature indexed by the National Library of Medicine.
- ClinicalTrials.gov: "Intranasal Insulin"
Registered interventional and observational studies, including status and phase.
- PubChem: "Intranasal Insulin"
Chemical structure, molecular properties, and bioactivity data.
Study-level citations for this compound are being verified against the primary sources before publication. The database queries above return the current indexed literature in the meantime.
Related Peptides in Cognitive
Semax
InvestigationalA synthetic heptapeptide analog of the ACTH(4-7) fragment (Met-Glu-His-Phe-Pro-Gly-Pro) with nootropic and neuroprotecti...
View detailsSelank
InvestigationalA synthetic analog of the endogenous tetrapeptide tuftsin (Thr-Lys-Pro-Arg) with an added Pro-Gly-Pro sequence for stabi...
View detailsCerebrolysin
InvestigationalA porcine brain-derived peptide preparation consisting of low-molecular-weight neuropeptides and free amino acids that m...
View detailsP21 (Peptide)
Research PhaseA small synthetic peptide derived from the active region of ciliary neurotrophic factor (CNTF) designed to promote neuro...
View detailsNo lawful pathway today
Intranasal Insulin is not FDA-approved and does not currently have a lawful prescription or compounding pathway in the United States, so there is nothing for us to sell you here and no consultation to book. That can change: eight peptides moved back to a lawful pathway in February 2026.
Tell me if the status changes
One email, only if this compound's regulatory standing actually moves. Not a newsletter, not a sales sequence.
Join the Association
Access exclusive peptide protocols, provider resources, and community support.
List Your PracticeDisclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed.